Nutromics

Nutromics is a pioneering Australian healthtech company dedicated to transforming the landscape of medical diagnostics through its proprietary Lab-on-a-patch® technology. By focusing on Continuous Molecular Monitoring (CMM), the company aims to shift healthcare from a reactive model to a proactive, data-driven approach. Their wearable platform utilizes advanced microneedle arrays and DNA-based electrochemical sensors to provide real-time, pain-free monitoring of biomarkers and therapeutic drugs, such as vancomycin, directly from interstitial fluid. Founded in 2017, the company has rapidly evolved from a research-focused startup into a significant player in the medical device sector. With a strong emphasis on clinical validation and innovation, Nutromics has successfully completed world-first human clinical studies, demonstrating the efficacy of their biosensing technology. By bridging the gap between laboratory-grade diagnostics and wearable convenience, Nutromics is working to reduce preventable deaths and improve patient outcomes in critical care and chronic disease management.

Mission: To revolutionize healthcare through Continuous Molecular Monitoring (CMM). Vision: To create a world with zero preventable deaths caused by a lack of timely, continuous diagnostic insights.

• Winner of the 2021 iAwards for Technology Platform Solution of the Year
• Successfully completed world-first in-human clinical study for DNA-based sensor technology
• Backed by major industry players including Dexcom Ventures
• Finalist in the prestigious MedTech Innovator Program

Sources

• Official Nutromics Website
• MedTech Innovator Program